FI963045A - Farmaseuttisesti aktiiviset yhdisteet ja liposomit ja menetelmä niiden käyttämiseksi - Google Patents

Farmaseuttisesti aktiiviset yhdisteet ja liposomit ja menetelmä niiden käyttämiseksi Download PDF

Info

Publication number
FI963045A
FI963045A FI963045A FI963045A FI963045A FI 963045 A FI963045 A FI 963045A FI 963045 A FI963045 A FI 963045A FI 963045 A FI963045 A FI 963045A FI 963045 A FI963045 A FI 963045A
Authority
FI
Finland
Prior art keywords
group
chain
liposomes
active compounds
pharmaceutically active
Prior art date
Application number
FI963045A
Other languages
English (en)
Swedish (sv)
Other versions
FI963045A0 (fi
FI116620B (fi
Inventor
Yong Wei
Eric Mayhew
Imran Ahmad
Andrew S Janoff
Original Assignee
Liposome Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposome Co Inc filed Critical Liposome Co Inc
Publication of FI963045A0 publication Critical patent/FI963045A0/fi
Publication of FI963045A publication Critical patent/FI963045A/fi
Application granted granted Critical
Publication of FI116620B publication Critical patent/FI116620B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI963045A 1994-02-02 1996-08-01 Farmaseuttisesti aktiiviset sfingolipidiyhdisteet ja liposomit sekä niitä sisältävät farmaseuttiset koostumukset FI116620B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19029594A 1994-02-02 1994-02-02
US19029594 1994-02-02
US9501490 1995-02-02
PCT/US1995/001490 WO1995021175A1 (en) 1994-02-02 1995-02-02 Pharmaceutically active compounds and liposomes, and methods of use therof

Publications (3)

Publication Number Publication Date
FI963045A0 FI963045A0 (fi) 1996-08-01
FI963045A true FI963045A (fi) 1996-08-01
FI116620B FI116620B (fi) 2006-01-13

Family

ID=22700754

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963045A FI116620B (fi) 1994-02-02 1996-08-01 Farmaseuttisesti aktiiviset sfingolipidiyhdisteet ja liposomit sekä niitä sisältävät farmaseuttiset koostumukset

Country Status (14)

Country Link
US (3) US5631394A (fi)
EP (2) EP0742789B1 (fi)
JP (1) JPH09508900A (fi)
AT (1) ATE195944T1 (fi)
AU (1) AU691886B2 (fi)
CA (1) CA2182485A1 (fi)
DE (1) DE69518627T2 (fi)
DK (1) DK0742789T3 (fi)
ES (1) ES2149350T3 (fi)
FI (1) FI116620B (fi)
GR (1) GR3034521T3 (fi)
NO (1) NO314405B1 (fi)
PT (1) PT742789E (fi)
WO (1) WO1995021175A1 (fi)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255336B1 (en) 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO1997010817A1 (en) * 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
EP0892638B1 (en) * 1996-04-04 2002-11-13 Cilag AG Liposome-based topical vitamin d formulation
US6274309B1 (en) * 1996-07-26 2001-08-14 Richard Kolesnick Method for the modulation of acid-sphingomyelinase-related apoptosis
CN1055640C (zh) * 1996-11-29 2000-08-23 沃维汉 人降钙素基因相关肽脂质体组合物及其制法
US6982142B2 (en) 1997-12-01 2006-01-03 John Wayne Cancer Institute Methods for screening therapeutically effective agents
AU3740000A (en) * 1999-03-25 2000-10-16 Center For Molecular Medicine And Immunology Sphingomyelin containing preparation for the enhancement of tumor therapy
US7683044B2 (en) * 1999-03-25 2010-03-23 Center For Molecular Medicine And Immunology Sphingomyelin therapy of autoimmune disease
US7820718B1 (en) * 1999-04-07 2010-10-26 Roger Williams Hospital Combinations of ceramide and chemotherapeutic agents for inducing cell death and uses thereof in treating cancer
TW502133B (en) 1999-06-10 2002-09-11 Wako Pure Chem Ind Ltd Resist composition, agent and method for reducing substrate dependence thereof
US6682545B1 (en) * 1999-10-06 2004-01-27 The Penn State Research Foundation System and device for preventing restenosis in body vessels
WO2001038295A1 (fr) * 1999-11-24 2001-05-31 Taisho Pharmaceutical Co.,Ltd. Derives de sphingosine
US6410597B1 (en) * 2000-02-25 2002-06-25 Virginia Commonwealth University Hydroxyalkyl amide analogs of ceramide
US6858383B2 (en) * 2000-12-22 2005-02-22 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
CA2453978C (en) 2001-07-16 2011-10-11 Genzyme Corporation Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors
EP1287815A1 (en) * 2001-08-31 2003-03-05 Cosmoferm B.V. Use of a sphingoid base for inhibiting ceramidase activity
US6916802B2 (en) * 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) * 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
US20070031480A1 (en) * 2003-03-07 2007-02-08 Lawrence Mayer Enhanced delivery of sphingolipids
WO2004087097A2 (en) * 2003-03-31 2004-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
BRPI0409663A (pt) 2003-04-25 2006-04-18 Penn State Res Found método e sistema para o envio sistêmico de compostos bioativos derivados de lipìdeo de detenção de crescimento
US7906122B2 (en) 2003-06-18 2011-03-15 Yissum Research Development Company Of The Hebrew University Of Jersusalem Sphingoid polyalkylamine conjugates for Hepatitis B virus vaccination
WO2004110496A1 (en) * 2003-06-18 2004-12-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingoid polyalkylamine conjugates for vaccination
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
CA2586761A1 (en) 2004-11-10 2006-05-18 Genzyme Corporation Methods of treating diabetes mellitus
JP2008520560A (ja) * 2004-11-15 2008-06-19 イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム 組合せ治療
JP4791082B2 (ja) * 2005-05-30 2011-10-12 株式会社クラレ リポソームおよびそれを含む皮膚外用剤
WO2007044748A2 (en) * 2005-10-11 2007-04-19 University Of Pittsburgh Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
ES2546181T3 (es) 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
US9217749B2 (en) 2006-05-31 2015-12-22 Lpath, Inc. Immune-derived moieties reactive against lysophosphatidic acid
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US8796429B2 (en) 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
AU2007329759B2 (en) 2006-10-27 2013-05-30 Lpath, Inc. Compositions and methods for binding sphingosine-1-phosphate
AU2007313822A1 (en) 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
EP2594565B1 (en) 2007-05-31 2018-10-24 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
KR20160085917A (ko) 2007-10-05 2016-07-18 젠자임 코포레이션 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법
WO2009132082A2 (en) * 2008-04-22 2009-10-29 Medical College Of Georgia Research Institute, Inc. Immunogenic compositions containing ceramide and methods of use thereof
WO2010014554A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
CN102271678B (zh) 2008-10-03 2017-06-30 简詹姆公司 2‑酰胺基丙醇型葡糖神经酰胺合成酶抑制剂
PL3599237T3 (pl) 2009-11-27 2021-09-27 Genzyme Corporation Kompozycja farmaceutyczna inhibitora syntazy glukozyloceramidowej eliglustatu do leczenia choroby Gauchera obejmującego dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 pacjenta
WO2013024843A1 (ja) * 2011-08-15 2013-02-21 国立大学法人 千葉大学 セラミド誘導体およびこれを用いたゴルジ体標識化蛍光プローブ
KR102423002B1 (ko) * 2021-02-17 2022-07-21 주식회사 엘씨에스바이오텍 신규 세라마이드, 그의 제조방법 및 그의 용도

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522803A (en) * 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US5030453A (en) * 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US4588578A (en) * 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US5169637A (en) * 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
US4721612A (en) * 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
US5008050A (en) * 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4975282A (en) * 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
US5059421A (en) * 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
JP2588729B2 (ja) * 1987-10-05 1997-03-12 塩野義製薬株式会社 スフィンゴシン誘導体
FR2637598B1 (fr) * 1988-10-06 1991-10-11 Agronomique Inst Nat Rech Nouveaux sphingophospholipides a inositol, leur obtention, et leur application comme inducteurs de resistance a diverses maladies cryptogamiques chez les vegetaux
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
DE4021082C2 (de) * 1990-07-03 1995-08-17 Hans Dr Lautenschlaeger Hautbehandlungsmittel mit hohen Lipidgehalten unter Verwendung eines Bilayer enthaltenden Systems, Salzen organischer Säuren, Alkohol und Stabilisator
AU653363B2 (en) * 1990-08-13 1994-09-29 Duke University Methods for inducing cell differentiation using ceramides
GB9022921D0 (en) * 1990-10-22 1990-12-05 Unilever Plc Cosmetic composition
GB9100816D0 (en) * 1991-01-15 1991-02-27 Unilever Plc Cosmetic composition
DE4201461A1 (de) * 1992-01-21 1993-07-22 Mueller Schulte Detlef Dr Mittel fuer die selektive tumortherapie auf der basis ferromagnetischer partikel - verfahren zu ihrer herstellung und verwendung

Also Published As

Publication number Publication date
CA2182485A1 (en) 1995-08-10
AU1871295A (en) 1995-08-21
WO1995021175A1 (en) 1995-08-10
ATE195944T1 (de) 2000-09-15
DK0742789T3 (da) 2000-11-13
EP1008342A3 (en) 2004-12-29
NO314405B1 (no) 2003-03-17
EP0742789A1 (en) 1996-11-20
FI963045A0 (fi) 1996-08-01
GR3034521T3 (en) 2000-12-29
EP0742789B1 (en) 2000-08-30
ES2149350T3 (es) 2000-11-01
EP1008342A2 (en) 2000-06-14
FI116620B (fi) 2006-01-13
US5677337A (en) 1997-10-14
AU691886B2 (en) 1998-05-28
NO963224D0 (no) 1996-08-01
US5631394A (en) 1997-05-20
JPH09508900A (ja) 1997-09-09
US5681589A (en) 1997-10-28
DE69518627D1 (de) 2000-10-05
PT742789E (pt) 2000-12-29
DE69518627T2 (de) 2001-01-11
NO963224L (no) 1996-09-27

Similar Documents

Publication Publication Date Title
FI963045A0 (fi) Farmaseuttisesti aktiiviset yhdisteet ja liposomit ja menetelmä niiden käyttämiseksi
AU7077894A (en) Immunosuppressant and antiallergic compounds, e.g. n-(3-oxohexanoyl) homoserine lactone
IL94444A0 (en) Retroviral protease inhibiting compounds
AU1533692A (en) Quaternized panthenol compounds and their use
EP0604657A4 (en) PHOSPHONIC DIESTER DERIVATIVE.
PL350775A1 (en) Pharmaceutical compounds
ZA9710292B (en) Atherosclerosis treatment
KR960007592A (ko) 신규한 피롤로카바졸
MY113518A (en) Benzothiazolone derivatives
ES2058620T3 (es) Compuesto de pirrolidina y uso farmaceutico del mismo.
HU9501466D0 (en) Glycopyranoside benzothiophenes
EP0521393A3 (en) Diclofenac salt, a method for the preparation thereof and pharmaceutical compositions containing it
TW287086B (fi)
TW275629B (fi)
IL103202A0 (en) Method for treating hypertension
GB8709547D0 (en) Organic compounds
DE69405999D1 (de) Pharmazeutisch wirksame enantiomere
EP0372582A3 (en) 6-aminoalkyl carbapenems
GB9617822D0 (en) Pharmaceutical compounds
ECSP951403A (es) Compuestos heterociclicos y fenilo
ATE188468T1 (de) Antiherpetische peptidomimetische verbindungen

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: TRANSAVE, INC.

Free format text: TRANSAVE, INC.

FG Patent granted

Ref document number: 116620

Country of ref document: FI

MA Patent expired